Media.Player

Method for culturing patient-derived cancer cells expedites treatment decisions for bladder cancer

總結

Michael M. Shen, Ph.D.

技術優勢

Ability to establish a cell line from only a small tumor sampleHigh efficiency rate (89%) with rapid cell growth timeframeCell lines can remain in culture for an extended period of timeCell lines can be frozen for long-term storage and thawed at a later date with normal growthPatient-derived cell lines would be specific to each bladder cancer case for personalized therapyPatent information:Patent PendingTech Ventures Reference: IR CU14280

技術應用

Modeling the efficacy of intravesical therapy agents to determine course of action in treating bladder cancer patientsUse for drug therapy development to treat bladder cancerUse for pathophysiology studies of bladder cancerModeling diseases related to unregulated cell growthCreation of a tissue library of cancerous tissue for research purposes (bladder cancer or otherwise)

詳細技術說明

Michael M. Shen, Ph.D.

*Abstract

None

*Inquiry

Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU14280

*Principal Investigation

*Publications

Barlow L, Chua CW, Lei M, DeCastro J, Badani K, Benson M, McKiernan J, Shen M. Poster: An individualized approach to bladder cancer treatment using patient-derived cell lines to predict response to chemotherapeutic agents. American Association for Cancer Research (AACR) Annual Meeting, San Diego, April 2014.

國家/地區

美國